Document is current
Any future updates will be listed below
-
Authors
Bentzer, Peter
Fjell, Chris
Walley, Keith R.
Boyd, John
Russell, James A.
-
Funding
Funding for this research was provided by:
Anna and Edwin Berger Foundation
ALF (18401)
Canadian Institutes of Health Research (44152)
- License Information
-
More Information
Article History
Received: 19 November 2015
Accepted: 19 March 2016
First Online: 12 April 2016
Compliance with ethical standards
:
: PB, CF, KRW, and JB report no conflicts of interest. JR is a founder, director, and shareholder in Cyon Therapeutics Inc. (developing a sepsis therapy). JR has share options in Leading Biosciences Inc. JR reports receiving consulting fees from Cubist Pharmaceuticals (now owned by Merck; formerly was Trius Pharmaceuticals; developing antibiotics), Ferring Pharmaceuticals (manufactures vasopressin and is developing selepressin), Grifols (sells albumin), MedImmune (regarding sepsis), Leading Biosciences (developing a sepsis therapeutic), La Jolla Pharmaceuticals (developing angiotensin II), CytoVale Inc. (developing a sepsis diagnostic), and Asahi Kesai (developing recombinant thrombomodulin).
